Vapreotide (Sanvar) is a synthetic somatostatin analog. It is used in the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and AIDS-related diarrhea.
Vapreotide attenuates SP-triggered intracellular calcium increases and NF-κB activation in a dose-dependent manner. Vapreotide also inhibits SP-induced IL-8 and MCP-1 production in HEK293-NK1R and U373MG cell lines. Vapreotide inhibits HIV-1 infection of human MDM in vitro, an effect that is reversible by SP pretreatment. In vivo: Vapreotide decreases portal pressure and blood flow of collateral circulation in rats with cirrhosis. Vapreotide administrated via the intravenous route is simple to use, with practically no contraindications and few, usually minor, side effects.
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.